{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} A Vaccine Shows Promise for the Treatment of HPV16-Associated CIN3 Lesions
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Learning Objectives
After completing this continuing education activity you will be able to:
- Summarize the methodology used to evaluate the clinical effectiveness of the Vvax001 vaccine.
- Explain the study results.
Learning Outcomes
By the conclusion of this activity, a majority of the participants will demonstrate knowledge of a clinical trial demonstrating that a therapeutic vaccine targeting human papillomavirus type 16 (HPV16) can induce regression in high-grade precancerous cervical lesions by achieving a passing score on the posttest.Disclosures
All authors and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- FL - BON 1.0 CH
- GA - BON 1.0 CH
- NM - BON 1.0 CH
- SC - BON 1.0 CH
- WV - BOERN 1.0 CH
Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0525
Published: May 2025
Expires: 6/4/2027
Sources:
Oncology Times
Required Passing Score: 4/5 (80%)
Specialties:
Oncology,
Women's Health